Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis

13 Aug 2024

Abstract excerpt

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown origin and the most common interstitial lung disease. However, therapeutic options for IPF are limited, and novel therapies are urgently needed. Histone deacetylases (HDACs) are enzymes that participate in balancing histone acetylation activity for chromatin remodeling and gene transcription regulation. Increasing evidence suggests...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39193364
DOI: 10.3389/fcell.2024.1426508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosisPMID 39193364Read ↗

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic OptionSemantic proximity Read ↗

Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosisSemantic proximity Read ↗

The role of histone deacetylases in inflammatory respiratory diseases: an updateSemantic proximity Read ↗

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory DiseasesSemantic proximity Read ↗

The Role of Histone Deacetylases in Acute Lung Injury—Friend or FoeSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)Semantic proximity Read ↗

The role of HDAC3 in inflammation: mechanisms and therapeutic implicationsSemantic proximity Read ↗

Targeting Transcription Factor Lysine Acetylation in Inflammatory Airway DiseasesSemantic proximity Read ↗

The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injurySemantic proximity Read ↗

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.